Asahi Kasei Pharma announces that Teribone™ 28.2 µg subcutaneous autoinjector (generic name: teriparatide acetate) for the treatment of osteoporosis with high risk of fracture has been listed on Japan's National Health Insurance (NHI) drug price standard today. The market launch of the product is scheduled for December 11, 2019.
The Teribone™ 28.2 µg subcutaneous autoinjector adds a new formulation option in addition to the conventional vial formulation of Teribone™ 56.5 µg subcutaneous injection*.
Teribone™ 28.2 µg subcutaneous autoinjector is designed to be easily used even by elderly patients, with a simple two-step process of taking off the cap, and pressing the injector point against the skin at the appropriate location. Because the patient doesn't necessarily need to see the needle, which is hidden in the safety needle cover, a reduction of anxiety is expected. Being a single-use disposable product, it is hygienic and requires no reattachment of a new needle. Needle stick injuries are prevented as the needle is hidden inside the locked safety needle cover after injection.
Asahi Kasei Pharma believes that it can make a significant contribution to the treatment of osteoporosis by providing this safe, reliable and convenient autoinjector as a new formulation option.
- The vial formulation of Teribone™ 56.5 µg subcutaneous injection is not approved for self-injection at home.
Product outline
Product name
Teribone™ 28.2 µg subcutaneous autoinjector
Generic name
Teriparatide acetate
Indication
Osteoporosis with high risk of fracture
Dosage and administration
For adults, ordinarily administered in a single 28.2 µg injection twice a week (one injection a day) for up to 24 months.
Manufacture and sale
Asahi Kasei Pharma Corp.
Approval
September 20, 2019
NHI price listing
November 27, 2019
Launch of sale
December 11, 2019
NHI price
¥6,018 per kit of 28.2 µg